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1. Introduction 
In Chapter 3 the rationale for a range of CAM products that are used in the management of 
autism was presented with the view to inform researchers and health care professionals 
about the theoretical or proven basis for a range of CAM products in autism. 
This Chapter is the second part of the two-part review and examines the evidence for 
efficacy and safety of a range of CAM products in autism. Each CAM product for which 
randomised controlled trials have been conducted has been assigned to a category of the 
Natural Standard Research Collaboration grading rationale for efficacy (Natural Standard 
Research Collaboration 2010). To determine safety of the range of CAM products 
investigated, all types of trials where specific a CAM product has been investigated in 
autism were examined. 
2. Aim  
To systematically review the literature to determine the efficacy and safety of a range of 
CAM products used in autism. Specifically, the following interventions were investigated: 
vitamins A, B, C and E, dimethylglycine (DMG), calcium, iron, magnesium, selenium, zinc, 
probiotics, digestive enzymes, colostrum, secretin, olive leaf extract, polyunsaturated fatty 
acids (PUFAs), melatonin, chelating agents (dimercaptosuccinic acid, DMSA & thiamine 
tetrahydrofuryl disulphide, TTFD), glutathione and glutamine.  
3. Method 
The method used to retrieve articles for the purposes of the review of efficacy and safety of 
CAM products used in autism was as described in Chapter 3.  
Randomised controlled trials or randomised cross-over trials that were retrieved via the 
method described in Chapter 3, were used to assess effectiveness of specific CAM products 
in individuals with autism spectrum disorder (ASD). The grading system used by the 
Natural Standard Research Collaboration (Natural Standard Research Collaboration 2010) 
was used to assign a rating (A to F) signifying the level of evidence that exists for the use of 
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each complementary medicine in treating autism. A rating A is assigned to strong positive 
evidence and a rating of F indicates strong negative evidence. 
Relevant articles were read in full by two independent reviewers and data extracted using a 
pre-defined protocol including study design, number and characteristics of subjects, 
interventions and comparisons, length of follow-up, outcome measures, and results. 
Randomised controlled trials, used to examine evidence for efficacy, were assessed for study 
quality and given a rating from 0 to 5 on the Jadad scale (Jadad et al. 1996). This scale 
awards points for description of randomisation, blinding and drop-outs with a score of 5 
indicating the highest study quality. Any discrepancies between reviewers were resolved by 
discussion. Studies published only in abstract form were excluded from the analysis of 
efficacy. Adverse effects reported in all relevant studies were summarised and assessed. 
Clinical trials of all designs were used to examine reported adverse effects of the CAMs 
products in the autism population. 
4. Results 
4.1 Efficacy 
Overall there is a distinct lack of good quality clinical evidence to support the efficacy of the 
wide variety of CAM products that are used in autism. There were no published studies of 
any kind conducted specifically examining efficacy for the following CAM products in 
autism: vitamin A or E, selenium, calcium, zinc, olive leaf extract, colostrum, 
Metallothionein promoter or glutamine. For the remainder of the CAM products 
investigated, various types of trials were retrieved. Evidence for efficacy was assessed based 
on findings from randomised controlled trials. For those CAM products where randomised 
controlled trials have been published, evidence for efficacy in autism was rated as being 
either unclear or conflicting for the majority of agents i.e. a Natural Standard Research 
Collaboration Efficacy Rating C as shown in Table 1.  
4.1.1 High dose pyridoxine and magnesium (HDPM)  
A total of 15 studies describing the administration of vitamin B6 and/or magnesium to 
children with autism were identified through the literature search (Lelord et al. 1978; 
Rimland et al. 1978; Barthelemy et al. 1980; Martineau et al. 1981; Lelord et al. 1982; 
Barthelemy et al. 1983; Jonas et al. 1984; Martineau et al. 1985; Martineau et al. 1986; 
Martineau et al. 1988; Martineau et al. 1989; Ménage et al. 1992; Tolbert et al. 1993; Findling 
et al. 1997; Kuriyama et al. 2002;). As shown in Table 2, there were three randomised 
controlled trials that examined the effects of pyridoxine and magnesium in autism that had 
a Jadad score of 3 or above and therefore were of sufficient quality to use to determine 
evidence for efficacy. A study by Kuriyama et al. (2002) comparing pyridoxine versus 
placebo found that verbal IQ improved in the treatment group while two other studies by 
Findling et al (1997) and Tolbert et al. (1993) found no significant differences in response 
between HDPM and placebo. The sample sizes of all studies were small i.e. n = 8, 10 & 15 
respectively. Notably, a study by Mousain-Bosc et al. (2006) found children with PDD had 
significantly lower magnesium prior to supplementation with HDPM which normalised 
following treatment with an improvement in PDD symptoms. According to the Natural 
Standard Research Collaboration grading rationale (Natural Standard Research Collaboration 
2010), vitamin B6 plus or minus magnesium for the treatment of autism as shown in Table 1 
would be assigned to category C. This corresponds to unclear or conflicting scientific evidence  
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Complementary Medicine 
Natural Standard 
Research Collaboration 
Rating 
Trials used to determine the 
Natural Standard Research 
Collaboration Rating 
Vitamin B6 + magnesium C 
Kuriyama et al. 2002; Findling et 
al. 1997; Tolbert et al. 1993 
Vitamin B12 C Bertoglio et al. 2010 
Multivitamins/minerals  
(Spectrum Support) 
C Adams&Holloway 2004 
Dimethylglycine (DMG) C 
Bolman &Richmond 1999; Kern et 
al. 2001 
Vitamin C C Dolske et al. 1993 
Probiotics C Parracho et al. 2010 
Digestive enzymes D Munasinghe et al. 2010 
Secretin F 
Williams et al. 2009 (Cochrane 
review that examined 14 
randomised controlled trials) 
Polyunsaturated fatty acids 
(PUFAs)  
C 
Amminger et al. 2007; Bent et al. 
2010  
Melatonin B 
Garstang&Wallis 2006; Wright et 
al. 2011 
All others 
Lack of scientific 
evidence 
 
Level of Evidence Grade A: Strong Scientific Evidence; B: Good Scientific Evidence; C: Unclear or 
conflicting scientific evidence; D: Fair Negative Scientific Evidence; F: Strong Negative Scientific 
Evidence. 
Table 1. Evidence for the efficacy of selected complementary medicines in treating autism 
on the basis that there is no apparent majority of the properly-conducted trials indicating 
evidence of benefit or ineffectiveness. In conclusion, the long-term administration of high-
dose vitamin B6 to autistic children should not be recommended, pending further research. 
There is a need for randomised, controlled clinical trials with adequate power to be 
performed in this population before efficacy can be confirmed.   
4.1.2 Vitamin B12, folinic acid and betaine 
A small case control study by James et al (2004) showed that the metabolic profile within the 
folate/methionine pathway was normalised in children with autistic disorder (AD) when 
they received supplementation with folinic acid and betaine for three months (n=8), 
particularly the ratio of S-adenosyl-methionine: S-adenosylhomocysteine (SAM:SAH), 
comparable to the profile in individuals without autism. The addition of vitamin B12 to this 
regimen for a further one month acted mainly on the trans-sulphuration pathway, 
increasing the ratio of reduced glutathione: oxidised glutathione (GSH:GSSG), although it 
also led to further normalisation of methionine metabolites. Clinical improvements in both 
speech and cognition were observed but these were not quantitatively measured. The same 
researchers conducted a larger intervention in 40 children with AD and reduced 
methylation capacity or GSH:GSSG in which they were supplemented with folinic acid and 
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methylcobalamin for 3 months (James et al. 2009). The new regimen, which used half the 
dose of folinic acid than their earlier study (James et al. 2004), improved the mean 
metabolite concentrations significantly after intervention, although they remained below 
those in unaffected control children. In the earlier 2004 study, objective behavioural 
measures were not reported. As these studies were not randomised controlled trials and 
behavioural measures were not quantitatively measured and reported, vitamin B12 and 
folinic acid plus or minus betaine for the management of autism would be assigned to the 
'lack of evidence' category of the Natural Standard Research Collaboration grading rationale  
4.1.3 Folinic acid 
Studies have reported the effect of treatment with folinic acid on low cerebrospinal fluid 
(CSF) levels of 5-methyltetrahydrofolate (5-MTHF) in a subgroup of children with autism 
and at least one symptom of cerebral folate deficiency (CFD) (Moretti et al. 2005; Ramaekers 
et al. 2007; Moretti et al. 2008). One of these studies showed that treatment with folinic acid 
resulted in improved autistic, motor and other neurological symptoms in young children 
(<3.5 years) and improvements in motor and neurological symptoms in older children, 
although there was no change in autistic symptoms in the older age group (Ramaekers et al. 
2007). It remains to be determined whether gains can be achieved with folinic acid 
supplementation in children with AD without CFD. As these studies were not randomised 
controlled trials, folinic acid for the management of autism would be assigned to the 'lack of 
evidence' category of the Natural Standard Research Collaboration grading rationale.  
4.1.4 Vitamin B12 
As summarised in Table 2, a double-blinded randomised placebo-controlled trial was 
recently published where participants (n=30) were administered either methyl-cobalamin or 
placebo for 6 weeks and then switched without washout for a further 6 weeks (Bertoglio et 
al. 2010). Overall, there was no significant change in GSH, GSH:GSSH or behaviour, 
however, 30% of participants showed a significant improvement against objective 
behavioural measures which correlated with improved plasma GSH and GSH:GSSH. 
Therefore, given there was no overall benefit but a benefit shown in a subgroup of children 
with autism, vitamin B12 for the treatment of autism would be assigned to category C of the 
Natural Standard Research Collaboration grading rationale as shown in Table 1. Further 
studies in the subgroup which show improvements in plasma GSH and GSH:GSSH with 
B12 treatment are warranted. 
4.1.5 Multivitamin/mineral supplement 
Multivitamins are widely implemented by caregivers of children with autism and one 
physician survey found 49% of respondents recommended their use in children with autism 
(Golnik&Ireland 2009). Adams & Hollloway (2004) conducted a 3-month pilot randomised 
controlled trial of a moderate dose multivitamin/mineral supplement (Spectrum Support II 
transitioning to III) in children with autism (n=20). Mothers completed a Global Impressions 
survey and results showed statistically significant improvements in sleep and gastrointestinal 
(GI) symptoms in those children taking the supplement versus placebo. Therefore this study 
shows Spectrum Support multivitamin/mineral supplement holds promise for the 
treatment of sleep and GI disturbance in autism . However, due to the small sample size it 
would be assigned to category C of the Natural Standard Research Collaboration grading 
rationale as shown in Table 1 and indicates a larger study is warranted. 
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4.1.6 Dimethylglycine (DMG)  
Although there are numerous anecdotal reports that DMG reduces autistic behaviours and 
improves speech, as summarised in Table 2, administration of low dose DMG demonstrated 
no statistically significant effect on autistic behaviours in two double-blind, placebo-
controlled trials (n = 8 & 37) (Bolman &Richmond 1999; Kern et al. 2001). Therefore, DMG 
for the treatment of autism would be assigned to category C of the Natural Standard 
Research Collaboration grading rationale, i.e. unclear or conflicting scientific evidence as 
shown in Table 1. This is on the basis that although there is an indication that DMG is 
ineffective in two randomised controlled trials, the sample sizes are too small to provide 
conclusive evidence. 
4.1.7 Vitamin C 
One small randomised double-blind, crossover study (n=18) reported decreased stereotypic 
behaviours in children who received ascorbic acid (Dolske et al. 1993). This study had a 
number of methodological flaws including a small sample size, heterogeneity of subjects, 
lack of ascorbate-free baseline and a lack of different, multiple dependent variables. In 
addition this study has not been replicated (Levy&Hyman 2003). As the study was of poor 
quality (i.e. a Jadad rating of 2) vitamin C as a treatment for autism is assigned to category C 
of the Natural Standard Research Collaboration grading rationale i.e. unclear or conflicting 
scientific evidence on the basis that there is no apparent majority of the properly-conducted 
trials indicating evidence of benefit or ineffectiveness. It is important to note that the use of 
vitamin C to prevent/treat deficiency (scurvy) in any individual would gain a Natural 
Standard Research Collaboration rating of A (strong scientific evidence), however the focus 
of this study is to examine the efficacy of vitamin C as a treatment for the disorder of autism. 
4.1.8 Iron 
An open-label uncontrolled study was undertaken as a pilot study to examine the effects of 
iron supplementation in children with autism (n=33, 2-10 years of age) (Dosman et al. 2007). 
The study examined effects on ferritin levels and sleep. An oral iron supplement at a dose of 
6 mg elemental iron/kg/day was administered for 8 weeks. Parents completed two sleep 
questionnaires, a three-day food record, and a Clinical Global Impression Scale 
questionnaire at baseline and after 8 weeks of iron supplementation. Blood samples were 
taken at baseline and post-treatment to determine serum ferritin and transferrin receptor 
and other blood chemistry. There was a significant increase (p < 0.001) in blood ferritin 
levels from 15.72 microgram/L at baseline to 28.8 microgram/L post-treatment. The Restless 
Sleep score improved significantly post-treatment (p< 0.04), however no statistically 
significant relationship was found between Restless Sleep score and ferritin concentration. 
One study has shown that iron levels may be problematic in children with ASD (Latif et al. 
2002), and clearly there are obvious benefits in treating iron deficiency. However, in terms of 
actually improving sleep and behaviour, the study conducted by Dosman et al. (2007) 
provides insufficient evidence for efficacy and is assigned to the 'lack of evidence' category 
of the Natural Standard Research Collaboration grading rationale. 
4.1.9 Probiotics 
Probiotics are widely used in autism, with one survey reporting 19% of medical 
practitioners recommend probiotics as a treatment in autism (Golnik&Ireland 2009). 
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Probiotics are live bacteria that, when administered, can provide health benefits to the host. 
As summarised in Table 2, a randomised double-blind, placebo-controlled, crossover-
designed probiotic feeding study was undertaken in children diagnosed with ASD. Children 
(n=17, 4-16 years of age) received either Lactobacillus plantarum WCFS1 for 3 weeks with a 3 
week wash out period. The overall indicator of behavioural/emotional disturbances was not 
significantly different between the two feeding periods. The observed benefit of the 
probiotic was a higher percentage of ‘formed’ stool samples compared to the placebo 
feeding, whilst the percentage of ‘hard’ stool samples was lower during probiotic feeding. 
No significant differences were observed between probiotic and placebo for GI disturbance 
(Parracho et al. 2010). Although probiotics hold promise as a treatment in autism they are 
currently assigned to category C of the Natural Standard Research Collaboration grading 
rationale as shown in Table 1. Notably Parracho et al.'s study (2010) only examined one type 
of probiotic feeding i.e. with Lactobacillus plantarum WCFS1 and thus even the benefits on 
stool consistency are not be generalisable to all probiotic interventions. 
4.1.10 Digestive enzymes 
One randomised double-blind, placebo-controlled, crossover-designed study (Munasinghe 
et al. 2010) examined the efficacy of 3 months treatment (with a 1 week washout) with a 
digestive enzyme (Peptizyde TM) in autism (n=27, mean age 69.4 months). As summarised in 
Table 2, this study found treatment with enzyme compared with placebo was not associated 
with clinically significant improvement in behaviour, food variety, GI symptoms, sleep 
quality, engagement with therapist, or the Language Development Survey Vocabulary or 
Sentence Complexity Scores (Munasinghe et al. 2010). As this study was of high quality (i.e. 
Jadad score of 5) and showed no benefit on a range of outcome measures it is assigned to 
category D of the Natural Standard Research Collaboration grading rationale. Notably, only 
one type of enzyme product was tested and results may not be generalisable to other 
digestive enzyme products that are used for this purpose.  
Although only randomised controlled trials were used to assess efficacy in this study, it is 
noteworthy that Brudnak et al. (2002) reported a case series with post-test outcomes 
following supplementation with a formulated combination of enzymes in children with 
ASD. Twenty-nine of the 46 subjects completed the trial, with personal issues, lack of 
palatability, and behavioural or medical side effects given as reasons for withdrawal from 
the study. The results of this study are limited due to its open, uncontrolled design, however 
Brudnak et al. (2002) reported a significant positive trend for each of the 13 parameters 
measured on the Symptom Outcome Survey.  
4.1.11 Secretin 
A systematic review of intravenous secretin for ASD was undertaken through the Cochrane 
Collaboration and published in 2005. An editorial update to this review in 2009 made no 
changes to the conclusions of the review (Williams et al. 2009). The objectives of the review 
were to examine whether intravenous secretin: a) improved the core features of autism; b) 
improved the non-core aspects of behaviour or function ; c) improved the quality of life of 
individuals with ASD and their carers; d) had a short term and long term effects on 
outcomes; e) caused harm. The review included literature covered by major health and 
biomedical databases and unpublished studies that could be located from 1998 to March 
2005. Studies were included if they were randomised controlled trials of intravenous 
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secretin comparing it with a placebo treatment in children or adults diagnosed with ASD, 
where at least one standardised outcome measure (such as a standardised checklist) was 
reported. Studies under consideration were evaluated for methodological quality and 
relevance by two independent reviewers using standardised Cochrane methods for 
assessing study quality. 
Fourteen studies met the inclusion criteria for the review. These studies represented data for 
618 children aged under 18 years. Nine studies used a cross-over design and five were a 
parallel design. The analysis of cross-over trials in the review was limited to the first phase 
to prevent biased underestimation of treatment effectiveness due to potentially inadequate 
wash-out periods. Different types of secretin were used in different studies including 
porcine, synthetic porcine and synthetic human secretin. Some studies used single doses of 
secretin while others used two or three doses of secretin 4 – 6 weeks apart. 
It was found that 25 established standardised outcome measures were reported in the 
included studies with no more than four studies reporting the same outcome measure. 
Outcomes were reported at between three and six weeks with no outcomes beyond six 
weeks post-intervention reported in the included studies. It was only possible to perform a 
meta-analysis on the outcome measure of the Childhood Autism Rating Scale (CARS). 
Ten studies presented information about core features of autism as an outcome measure. 
Analyses of outcome measures including subscales of the Autism Behavior Checklist (ABC), 
the Autism Diagnostic Observation Scale (ADOS), the Childhood Autism Rating Scale 
(CARS), Gilliam Autism Rating Scale: Autism Quotient and Autism Behavior Checklist 
found no significant differences between secretin and placebo. Overall it was concluded that 
the “RCTs of efficacy of secretin in autism have not shown improvements for core features 
of autism”. Overall, analysis of individual areas such as communication, behaviour, affect, 
visio-spatial skills and quality of life found no conclusive evidence in favour of secretin.  
The authors concluded that there was no evidence that secretin was effective in ASD and 
should not be recommended as a treatment. While no conclusions could be drawn about the 
effectiveness of secretin for certain subgroups of people with autism, it was suggested that 
further explorations of effectiveness in such subgroups should only be undertaken if there is 
a biologically plausible explanation for effectiveness in these groups. Secretin is therefore 
assigned to category F of the Natural Standard Research Collaboration grading rationale i.e. 
strong negative evidence for efficacy as shown in Table 1. 
4.1.12 Polyunsaturated fatty acids (PUFAs) 
PUFAs (also called omega -3 and -6 fatty acids), are recognised as vital building blocks for 
developing neurological systems. These essential fatty acids (EFAs) are present in fish oils, 
evening primrose oil and linseed (flaxseed) oil (Bell et al. 2004). A study by Green et al. 
(2006) revealed that 27.8% of caregivers of children with autism implemented PUFAs in 
their affected child. One survey reported PUFAs are recommended by 25% of medical 
practitioners for the management of autism (Golnik&Ireland 2009). 
As summarised in Table 2, one small randomised controlled trial (n = 13) investigating the 
efficacy of PUFAs (1.5g/day) in autism noted non-significant improvements in 
hyperactivity and stereotypy after 6 weeks treatment (Amminger et al. 2007). Another 
randomised controlled trial by Bent et al. (2010) examined PUFAs (1.3 g/day) for the 
treatment of hyperactivity in 27 children with ASD. They also found there were non-
significant improvements after 12 weeks in hyperactivity, as measured by the ABC. The 
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remaining five studies, four uncontrolled trials in children and one case report were small (n 
= 30, 22, 19, 9, and 1) with four (Johnson&Hollander 2003; Bell et al. 2004; Patrick&Salik 
2006; Meguid et al. 2008) reporting improvements in a wide range of outcomes including 
language and learning skills, parental observations of general health and behaviour, a 
clinician administered symptom scale, and clinical observations of anxiety. In contrast one 
uncontrolled trial in young adults with severe autism did not show a benefit (Politi et al. 
2008). 
In summary, the small sample size for both PUFA randomised controlled trials limits the 
conclusions that can be drawn. Although both studies were of high quality, and showed a 
lack of significant effect overall (but with a trend towards improvements in hyperactivity), 
the sample sizes are too small to give a conclusion of negative evidence. Therefore, the 
evidence for the efficacy of PUFAs in autism is currently inconclusive and PUFAs are 
assigned to category C of the Natural Standard Research Collaboration grading rationale. 
4.1.13 Melatonin 
Melatonin is another complementary medicine that is currently receiving attention in the 
management of sleep problems in autism. One survey found 25%of medical practitioners 
reported they recommend melatonin as a treatment in autism (Golnik&Ireland 2009) As 
summarised in Table 2, two randomised controlled trials (n=7 & 17) have been performed in 
autism that suggest melatonin is effective at reducing sleep latency, or time taken for 
initiation of sleep, and total sleep time in children with sleep problems and autism 
(Garstang&Wallis 2006; Wright et al. 2011). Further, one of the trials also showed melatonin 
improved the number of wakings per night (Garstang&Wallis 2006) and the other showed it 
improved daytime behaviour (Wright et al. 2011). Therefore on the basis of the findings in 
the two randomised controlled trials, melatonin is assigned to category B of the Natural 
Standard Research Collaboration grading rationale as shown in Table 1.  
Other types of trials also support the benefits of melatonin in the treatment of sleep 
disturbance in autism. There have also been two open trials conducted in a population of 
subjects with ASD (Paavonen et al. 2003; Giannotti et al. 2006). Paavonen et al. (2003) found 
a statistically significant reduction in sleep latency with melatonin administration to 15 
children with Asperger's Syndrome (AS) and Giannotti et al. (2006) found sleep patterns of 
all children with autism (n=20) improved during treatment. There were significant 
reductions in bedtime resistance and number and duration of night awakenings, and a 
significant increase in sleep duration. Andersen et al. (2008) and Galli-Carminati et al. (2009) 
have conducted observational retrospective trials in autistic populations (n= 107 children & 
6 adults respectively). Andersen et al.'s (2008) melatonin study found parents of 27/107 
(25%) children no longer reported sleep concerns after initiation of melatonin. Parents of 
64/107 (60%) of children reported improved sleep but with ongoing concerns. Parents of 14 
children (13%) continued to report sleep problems as an ongoing concern with only 1 child 
(1%) having worse sleep after starting melatonin, and 1 child having undetermined response 
(1%). Melatonin resulted in improvements in adults including length of sleep, time to fall 
asleep, nocturnal awakenings and early morning awakenings (Galli-Carminati et al. 2006).  
4.1.14 Chelating agents 
Approved uses for chelation therapy include heavy metal poisoning and digitalis toxicity, 
although it used in an off-label manner in autism. Practitioners are using a variety of 
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chelating agents and routes of administration for children with ASD, with oral 
dimercaptosuccinic acid (DMSA), also known as succimer, probably the most common. 
Several of the agents are not approved for use or are given through unlicensed routes of 
administration such as rectally or transdermally. A 5-year old child with autism died after 
being administered intravenous edetate disodium (Atwood&Woeckner 2009). The survey 
conducted by Golnik and Ireland (Golnik&Ireland 2009) reported that 61% of medical 
practitioners surveyed discouraged caregivers' use of chelation in the management of 
autism. 
A study conducted by Adams et al. (2009a; 2009b) examined the effects of oral DMSA as a 
chelating agent in children with a diagnosis of ASD. While the study was designed as a 
randomised double-blind study, the complex study design and carry-over effects from the 
first round of DMSA administered to all participants in the first phase of the study meant 
that the study lacked a true placebo control group. Essentially the study compared the 
effects of one round of DMSA therapy (and 6 rounds of placebo) with 7 rounds of DMSA. A 
round of DMSA therapy consisted of oral DMSA 10mg/kg administered three times a day 
for three days. This was followed by 11 days of no DMSA. Patients randomised to receive a 
topical reduced glutathione lotion (180 mg reduced l-glutathione/day) in the initial phase of 
the study received the DMSA therapy (up to 7 rounds in total) in the second study phase, 
while those receiving a placebo lotion received placebo in the second phase. A total of 82 
children were enrolled with 65 completing phase one and 41 completing phase two. Effects 
on urinary excretion of toxic metals and blood chemistry were examined, with a single 
round of DMSA found to cause a significant increase urinary excretion of lead, tin and 
bismuth and normalisation of red blood cell glutathione levels. Effects on behaviour were 
also assessed using a variety of measures including the Autism Diagnostic Observation 
Schedule (ADOS); Severity of Autism Scale (SAS); Pervasive Developmental Disorders – 
Behaviour Inventory (PDD-BI), Autism Treatment Evaluation Checklist (ATEC), and 
Parental Global Impressions questionnaire. Both the groups receiving one round and seven 
rounds of DMSA therapy were found to have significant improvements compared to 
baseline using most of these measures. However the differences in improvement between 
the groups were not significant. 
Another uncontrolled study assessed a combination of DMSA (administered orally at 
10mg/kg three times a day) with the anti-androgen leuprolide acetate (administered 
intramuscularly and subcutaneously) in 11 children with ASD (Geier and Geier, 2006). 
DMSA was to be administered transdermally if oral dosing caused severe GI disturbance. 
However, the number of participants, if any, experiencing GI disturbances was not reported. 
It was reported that the treatment had no adverse effect on kidney, thyroid or liver function 
tests. Children in the study received vitamin and mineral supplementation during the study 
and no effects on serum potassium, calcium, iron, magnesium, copper or zinc were 
observed. 
On the basis that these chelation trials were not properly conducted randomised controlled 
trials chelation for the management of autism would be assigned to the 'lack of evidence' 
category of the Natural Standard Research Collaboration grading rationale.  
4.1.15 Others  
No studies of any description investigating use in children with autism were located for the 
remainder of the interventions under investigation i.e. calcium, selenium, colostrum, 
glutamine, magnesium, metallotheionein, olive leaf extract, vitamin A or vitamin E. Hence, 
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the remaining interventions are assigned to the ‘lack of evidence’ category of the Natural 
Standard Research Collaboration grading rationale with respect to their use in the 
management of autism. It is important to remember that, as with vitamin C, 
supplementation with vitamin A, vitamin E, calcium and magnesium to treat or prevent 
deficiency in any individual would gain a Natural Standard Research Collaboration rating 
of A (strong scientific evidence). The focus of this study, however, was to examine their 
efficacy when used to specifically reducing the symptoms of autism, where they all lacked 
evidence for use.  
 
Reference 
No. of 
Subjects 
Patient 
Characteristics 
Intervention Comparison 
Length of 
Follow-up 
Outcome 
Measure(s) 
Results 
Funding 
Source 
Comments 
Trials of pyridoxine/magnesium 
Findling et 
al. (1997) 
12 patients 
enrolled, 10 
completed the 
study (2 
patients 
withdrew 
during two 
week lead-in 
period due to 
refusal to take 
study 
medicine). 
Aged 3-17, met 
Diagnostic and 
Statistical Manual 
of Mental 
Disorders (DSM-
III-R) criteria for 
autistic disorder, 
all living at home 
with a 
parent/guardian.  
Exclusion criteria: 
Significant past or 
current medical or 
neurological 
disorder, use of a 
psychotropic 
agent within 3 
months prior to 
start of study. 
Pyridoxine 
30mg/kg/day (max. 
1g) + Mg. oxide 
10mg/kg/day (max. 
350mg) 
Doses given twice 
daily at 8am and 
12pm. All subject s 
received placebo for 
the first two weeks 
(baseline period), 
after which they 
were randomised 
and received either 
treatment or placebo 
for four weeks, and 
then the opposite for 
the next four weeks. 
Placebo 
(identical 
appearance, 
efforts made to 
match taste) 
At baseline, all 
subjects 
received 
placebo for 2 
weeks in a 
single-blind 
fashion before 
randomisation. 
Subjects 
were 
evaluated 
every other 
week for a 
10-week 
period. 
Childhood 
Autism Rating 
Scale (CARS), 
Clinical Global 
Impression scale 
(CGI scale), 
Children’s 
Psychiatric 
Rating 
Scale(CPRS),  
Obsessive 
Compulsive Scale 
(OCS). 
ANOVA revealed 
no statistically 
significant effects of 
vit.B6 + Mg. on any 
of the outcome 
measures. 
50% of patients had 
a  30% reduction in 
CPRS score during 
the placebo lead-in 
phase of the study. 
Not 
specified 
Jadad score 
= 4 
Kuriyama 
et al. (2002) 
15 patients 
were recruited, 
but four met 
the exclusion 
criteria. 11 
completed the 
baseline study, 
3 were then 
excluded 
based on 
immeasurable 
IQs. 
Therefore 8 
patients were 
randomised (4 
in treatment 
group, 4 in 
placebo). 
Met DSM-IV 
criteria for PDDs, 
had expressive 
verbal disorders, 
developmental 
motor 
coordination 
disorders and 
hypersensitivity 
to sound, aged 6-
17. 
Exclusion criteria: 
History of 
epilepsy or an 
epileptiform EEG, 
use of a 
psychotropic 
agent within 3 
mths of starting 
the study, 
inability to 
measure IQ, brain 
image 
abnormalities on 
MRI, history of 
homocystinuria or 
fragile-x 
syndrome. In both 
groups, one child 
had AS and three 
PDD-NOS. 
Pyridoxine 100mg in 
powder form once 
daily for the first 2 
weeks, 100mg twice 
daily for the second 2 
weeks (after 
breakfast and after 
dinner). 
 
Placebo 
(powder form, 
identical in 
appearance 
and taste). 
Subjects 
were 
evaluated 
at baseline 
and after 4 
weeks of 
treatment. 
Changes in IQ 
scores (both 
verbal IQ and 
performance IQ) 
using the 
Wechsler 
Intelligence Scale 
for Children-III 
(WISC-III), social 
quotient (SQ) 
scores measured 
with the Social 
Maturity Scale 
(SM) test 
assessed by the 
subjects’ parents. 
There was a 
statistically 
significant increase 
in verbal IQ in the 
vit.B6 group relative 
to the placebo 
group, although 
verbal IQ did 
increase in both 
groups (by 11.2 in 
the treatment group 
and by 6.0 in the 
placebo group). The 
difference was still 
significant after 
controlling for sex, 
age, body weight, 
interval between 
tests and baseline 
verbal IQ using 
ANOVA. 
No significant 
difference in 
performance IQ and 
SQ scores was 
found. 
Not 
specified 
Jadad score 
= 5 
Limited by 
small sample 
size and 
short-term 
nature 
Mg was not 
given 
Tolbert et 
al. (1993) 
15 patients 
were 
randomised. 
A further 5 
subjects not 
receiving any 
treatment 
served as 
controls. 
Ages 6-18, all 
diagnosed with 
autism according 
to the DSM-III-R 
criteria, all 
residential 
students and 
receiving a 
standardised diet. 
No subjects had 
lactose 
intolerance, no 
pyridoxine 
deficiencies were 
Pyridoxine 
200mg/70kg/day in 
50mg tablets in 
divided doses. 
Magnesium 
100mg/70kg/day in 
27mg tablets in 
divided doses. 
Placebo 
(matching 
tablets) and 
control. 
Group 1: 
treatment for 
20 weeks then 
placebo for 10 
weeks 
Group 2: 
treatment for 
10 weeks, 
placebo for 10 
weeks, 
Subjects 
were 
evaluated 
after 
baseline 
and after 
each of 
three 10-
week 
blocks (i.e. 
30 weeks) 
Ritvo-Freeman 
Real Life Rating 
Scale for Autism 
(R-F) 
- quantitates 47 
specific 
behaviours 
grouped into 5 
subscales: 
sensory-motor, 
social, affective, 
sensory 
responses 
language. 
No significant 
differences among 
the three groups at 
any of the time 
points. 
There was a 
statistically 
significant reduction 
in scores across the 
time period for each 
group, possible due 
to other non-
pharmacological 
therapy that patients 
Not 
specified 
Jadad score 
= 3 
This study 
specifically 
used much 
lower doses 
of 
pyridoxine 
than 
previous 
studies in an 
attempt to 
reduce the 
risk of 
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identified. treatment for 
10 weeks. 
(after 5-week 
baseline 
period) 
Raters observed 
subjects involved 
in classroom 
activities from a 
room equipped 
with one-way 
mirrors and 
sound 
amplification.  
were receiving 
throughout the trial. 
peripheral 
neuropathies
. 
 
Trials of dimethylglycine (DMG) 
Bolman 
and 
Richmond 
(1999) 
10 were 
recruited, 8 
completed full 
testing. 
Ages 4-30, 
diagnosed 
according to 
DSM-III-R 
criteria, not taking 
other medication 
within one month 
prior to the study. 
DMG tablets, doses 
varied with weight 
(from 125mg/day for 
under 70lbs to 
375mg/day for over 
120lbs) 
Look-alike 
placebos 
2-week 
baseline 
period, 4 
weeks of either 
DMG or 
placebo, 2-
week washout 
period, 4 
weeks of 
placebo or 
DMG, 2-week 
baseline 
period. 
14 weeks (3 
½ months) 
Campbell-NIMH 
14-point Autism 
Rating Scale 
(ARS)(patients 
were videotaped 
weekly following 
a semi-structured 
set of guidelines 
in a playroom) 
An experimental 
10-item checklist 
developed by 
Rimland 
Individualised 
scales developed 
with help of 
parents (3 scales) 
Videotaping (ARS): 
no significant 
changes in 
behaviour observed. 
Experimental 
checklist: no 
significant 
differences between 
any of the study 
periods 
Individualised 
scales: From a group 
total of 55 scale 
items, 5 showed 
improvement with 
DMG vs. placebo, 14 
worsened and 36 
showed no 
difference. 
Not 
specified 
Jadad score 
= 3 
Only 3 out of 
8 parents 
could 
correctly 
guess during 
which 
period their 
child had 
taken DMG 
or placebo 
(less than 
chance). 
Kern et al. 
(2001) 
39 began the 
study, 37 
completed it 
Ages 3-11, 
diagnosis of 
autism or 
pervasive 
developmental 
disorder (DSM-
IV) 
7 children were 
on psychoactive 
medications (held 
constant 
throughout the 
study). 
Foil-wrapped 125mg 
DMG tablets (no. of 
tablets taken varied 
with weight, from 
125mg/day for 
under 40lbs to 
625mg/day for over 
130lbs). 
Identical 
placebo tablets 
(mannitol 
125mg) 
4 weeks Behavioural 
Assessments 
(Vineland 
Maladaptive 
Behaviour 
Domain, 
Aberrant 
Behaviour 
Checklist) 
Neurologic 
assessments 
Combined analysis 
of behavioural 
assessments 
revealed a 
significant 
improvement over 
the 4 weeks across 
all subjects (both 
placebo and 
treatment). There 
was no difference in 
improvement 
between the DMG 
group and the 
placebo group. No 
effect of DMG on 
any of the 
behavioural 
measures was 
observed. 
DMG treatment did 
not affect the 
neurological status. 
Not 
specified 
Jadad score 
= 4 
Parents 
reported 
improvemen
t in 58% of 
the DMG 
group and 
53% of the 
placebo 
group. 
Parents 
reported 
worsening in 
16% of the 
DMG group 
and 32% of 
the placebo 
group 
Trials of ascorbic acid 
Dolske et 
al. (1993) 
18 
(13 male and 5 
female). 
Inclusion: subjects 
diagnosed under 
the DMS-ІІІ-R 
criteria by two 
independent child 
psychiatrists, no 
lactose 
intolerance and 
plasma ascorbate 
levels >30µg/ml 
i.e. within normal 
range. Prior to the 
initiation of the 
study, subjects 
ascorbic acid 
supplementation 
ranged from 0-
4g/70kg/day. 
Participants were 
aged between 6 
and 19 years 
(mental age 
ranged from 2.0-
6.7, IQs ranged 
from <20-65). 
Subjects received 
a standardised 
diet throughout 
the duration of 
the study 
Ascorbic acid was 
administered at 
8g/70kg/day in 
500mg tablets, 
divided into two or 
three separate doses. 
Phase 1: 
Initially all subjects 
received ascorbic 
acid for a ten-week 
block.  
Phase 2: 
After the first ten-
week block, half the 
subjects were 
randomly assigned 
to continue to receive 
the ascorbic acid 
(Group 1) and the 
other half to receive a 
placebo (Group 2) for 
an additional ten 
weeks. 
Phase 3: 
For the final ten 
weeks the treatments 
were reversed. 
Matching 
placebo tablet 
(film coated 
and identical 
in 
appearance). 
Each 
treatment 
phase 
lasted 10 
weeks and 
behaviours 
were rated 
weekly 
using the 
R-F scale. 
The weekly 
R-F scores 
(total and 
each 
subscale) in 
each 10-
week block 
were 
averaged 
for each 
subject. 
30-week 
trial 
overall. 
R-F was used as 
an instrument to 
determine drug 
treatment 
evaluation.  
Raters observed 
subjects 
participating in 
routine 
classroom 
activities from an 
observation room 
equipped with 
one-way mirrors 
and sound 
amplification. 
Comparison of total 
scores revealed a 
significant 
interaction when 
comparing Phase 2 
and Phase 3 
(p=0.02).  
Behaviour worsened 
in group 1 when 
going from 
ascorbate (Phase 2) 
to placebo (Phase 3), 
where as behaviour 
improved in group 2 
when going from 
placebo (Phase 2) to 
ascorbate (Phase 3). 
 On the sensory 
motor scale 
(subscale 1), a 
significant 
interaction was 
found (group x 
phase 2 and 3) 
p=0.01. No other 
subscales revealed 
significant findings 
for main effects of 
group and phase 
interaction. 
Not stated Jaded score= 
2 
Article did 
not report 
any adverse 
effects. 
Small 
sample size, 
hetero-
geneous 
population, 
lack of 
ascorbate-
free baseline, 
confound-
ing 
neuroleptic 
variable, lack 
of different 
multiple 
dependent 
measures.  
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Nine of the 
children were on 
neuroleptics 
concurrent with 
the study. Prior to 
the study, the 
neuroleptic doses 
had been 
stabilised and 
were maintained 
throughout the 
study. 
There were no 
significant 
differences (p>0.05) 
between R-F total 
scores and subscales 
of children receiving 
vs not receiving 
neuroleptic 
medication during 
the initial 10-week 
phase of the trial. 
Therefore this 
medication variable 
was not included in 
the subsequent 
analyses. 
Trials of vitamin B12 
Bertoglio et 
al. 2010  
30 cases Children aged 3-8 
diagnosed with 
autism with DSM-
IV–TR and 
Autism 
Diagnostic 
Observation 
Schedule (ADOS) 
plus non-verbal 
IQ ≥49 measured 
by Wechsler 
Preschool and 
Primary Scale of 
Intelligence, 
Mullen Scales of 
Early learning or 
Wechsler 
Intelligence Scale 
for Children. 
Methyl-cobalamin 
64.5 μg/kg sc for 6 
wks followed by 
cross-over for 6 wks 
(no washout period). 
Placebo 12 week 
trial was 
followed by 
6 month 
open label 
for 22 cases 
Plasma GSH and 
GSH:GSSH 
linked to Global 
Clinical 
Impressions 
Score and other 
objective 
behavioural 
measures 
Overall, no 
significant difference 
in GSH, GSH: GSSH 
or behavioural 
outcomes. 
No serious adverse 
events were 
reported, only 
hyperactivity and 
increased mouthing 
of objects.  
 
Institute of 
the Univer-
sity of 
California, 
Davis 
Medical 
Centre 
Jadad score 
= 4 
Increased 
GSH, & 
GSH:GSSH 
and 
improved 
behavioural 
outcomes in 
9/30 
children 
which were 
identified as 
a “responder 
group”. 
Trials of multivitamin supplements 
Adams et 
al. (2004) 
25 subjects 
were enrolled, 
5 dropped out 
for varying 
reasons (20 
completed - 9 
in placebo 
group, 11 in 
supplement 
group) 
Ages 3-8 yrs, 
diagnosis of ASD 
by a psychiatrist, 
no changes in any 
treatment 
therapies within 2 
months prior to 
the start of the 
study, no prior 
use of a 
multivitamin/mi
neral supplement 
other than a 
standard 
children’s 
multivitamin/mi
neral. 
Spectrum Support II 
-dosage was 
increased to 
maximum over 24 
days and then held 
constant until day 34. 
Gradual transition 
during days 35-50 to 
Spectrum Support III 
which was continued 
until day 90. 
Full dosage: 
1ml/5lbs 
bodyweight three 
times daily with 
food. 
Placebo, 
matched to 
colour and 
consistency. 
3 months Global 
Impressions 
survey filled out 
by mothers 
 
Mothers reported 
statistically 
significant 
improvements in 
sleep and GI 
symptoms in those 
children taking the 
supplement versus 
placebo. 
 
Not 
specified 
Jadad score 
= 4 
Spectrum 
support is a 
liquid multi-
vitamin 
prepara-tion 
with a 
moderate 
level of 
vit.B6 and no 
copper 
 
Trials of probiotics 
Parracho et 
al. (2010) 
39 subjects, 
Group I 
(n=19), Group 
II (n=20) 
commenced 
the study. 17 
participants 
withdrew 
before end of 
first arm, 8 
from group I 
and 9 from 
group II. 3 
subjects 
withdrew due 
to adverse 
effects, 1 with 
rash, 1 with 
diarrhoea and 
1 with weight 
loss in feeding 
period.  A 
further 2 
subjects 
withdrew after 
first feeding 
arm and 3 
after first 
Children with 
ASD aged 4-16y  
Lactobacillus 
plantarum WCFS1 
(4.5x1010 colony-
forming units per 
capsule). Probiotic 
feeding for 3 wks 
followed by cross-
over for 3 wks (3 
week washout 
period). 
Placebo 12 weeks DBC 
administered 
immediately 
prior to 
commencing the 
feeding period 
i.e. baseline (B1), 
at the end of each 
feeding (F1 & F2) 
and washout 
period (W1 & 
W2).  
Two faecal 
samples were 
taken in the week 
prior to the study 
(commencing B1 
& B2) and at F1, 
F2, W1 and W2 
and bacterial 
populations 
examined. 
Bowel function 
and GI 
symptoms were 
also determined. 
The overall indicator 
of 
behavioural/emotio
nal disturbances i.e. 
Total Behaviour 
Problem Score 
(TBPS) was not 
significantly 
different between 
the two feeding 
periods.  
Probiotic feeding 
resulted in a higher 
percentage of 
‘formed’ stool 
samples 
(73.3 %) compared 
to the placebo 
feeding (64.8 %), 
whilst the 
percentage of ‘hard’ 
stool samples was 
lower during 
probiotic feeding. 
No significant 
differences were 
observed between 
probiotic and 
Not 
stated 
Jadad score = 
5 
Encapsulation 
of both 
placebo and 
probiotic, and 
blind coding 
of the 
capsules, was 
performed by 
Orafti 
(Belgium).  
Adverse 
effects 
monitored for. 
Lactobacillus 
plantarum 
WCFS1 and 
the placebo 
were supplied 
by Nizo Food 
Research, The 
Nether-lands. 
High drop-out 
rate from 
study affected 
statistical 
power  
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washout. 17 
subjects 
completed 
study (9 from 
group I and 8 
from group II). 
placebo for GI 
symptoms 
(abdominal pain, 
intestinal bloating 
and flatulence) 
Trials of digestive enzymes 
Munasingh
et al. (2010) 
43 subjects, 27 
completed 
intervention. 3 
were lost to 
follow up; 2 
from Sequence 
1 (S1) & 1 from 
Sequence (S2). 
1 subject 
withdrew due 
to family 
issues (S1), 4 
because of 
perceived 
behaviour 
deterioration 
(3 from S1 & 1 
from S2), 5 due 
to difficulties 
with capsule 
administration 
(4 from S1 & 1 
from S2) and 3 
gave no reason 
(S2). 
Children 
diagnosed with 
AD or PDD-NOS 
with the DSM-IV. 
Mean age was 
69.4 months. 
Digestive Enzyme 
S1 received 
Peptizyde TM for 3 
months, 
then crossed over 
and received 
placebo.  
S2 received placebo 
for 3 months, then 
crossed over and 
received PeptizydeTM 
for 3 months. (1 week 
washout period 
between treatment 
sequences)  
Placebo 6 months 
and 1 week 
Global Behaviour 
Rating Scale 
(GBRS), 
Additional 
Rating scale 
(ARS), Language 
Development 
Survey (LDS) 
No significant 
difference on the 
GBRS, ARS and LDS 
questionnaires. A 
small statistically 
significant 
improvement on 
enzyme therapy was 
seen for the food 
variety scores that 
was not deemed 
clinically significant. 
Not stated Jadad score 
= 5 
Enzyme and 
placebo 
provided by 
Houston 
Nutraceutica
ls 
Trials of polyunsaturated fatty acids (PUFAs) 
Amminger 
et al. 
(2007)
  
13 subjects, 
PUFA (n =7) 
or placebo 
(n =6). One 
individual 
from the 
placebo group 
withdrew 
from the trial 
after 2 weeks 
because of GI 
complaints 
and lack of 
symptom 
improvement. 
Children with 
average age 10.4, 
(5-17y) diagnosed 
with autism with 
DSM-IV–TR and 
ADOS 
7X 1g capsules of 
Menhaden fish oil 
containing 840 mg 
eicosa-pentaenoic 
acid (EPA), 700 mg 
docosa-hexaenoic 
acid (DHA) & 7 mg 
Vitamin E (i.e. 1.54g 
of PUFA/day) for 6 
weeks 
Placebo i.e. 
coconut oil 
with 1 mg fish 
oil and 1 mg 
vitamin E 
6 weeks Aberrant 
Behavior 
Checklist (ABC) 
Non-significant 
trends towards 
improvement. 
Mild adverse events 
reported included 
fever in the 
experimental group 
and headache and 
insomnia in the 
placebo group. 
Not stated Jadad score 
= 4 
Small 
sample size  
Trends for 
improve-
ment in 
hyper-
activity, but 
not 
statisticallysi
gnificant. 
Omega 
Protein Co-
operation, 
provided 
medication 
Bent et a. 
(2010) 
25 subjects 
included in 
analysis, 
PUFA (n=13) 
or placebo 
(n=12). PUFA 
group, lost to 
follow-up 
(n=1, disliked 
taste), 
discontinued 
intervention 
(n=4, 2 
disliked taste, 
1 rash, 1 GI 
symptoms). 
Placebo group, 
lost to follow-
up (n=1, blood 
draw anxiety), 
discontinued 
intervention 
(n=2, 1 
disliked taste, 
1 increased 
self-
stimulatory 
behaviour) 
Children ages 3-8 
diagnosedwith 
ASD (with the 
ADOS, social 
communication 
questionnaire 
(SCQ) & DSM-IV-
TR) and 
hyperactivity 
(with the ABC) 
PUFAs were 
provided 
as orange-flavoured 
pudding packets 
(Coromega_, Vista, 
CA) containing 650 
mg of omega-3 fatty 
acids, including 
350 mg of EPA and 
230 mg of 
DHA, given twice 
daily for a daily 
dose of 1.3 g of 
PUFAs (and 1.1 g of 
DHA/EPA) for 12 
weeks. 
Placebo 
packets had 
the same 
orange-
flavoured 
pudding with 
an identical 
appearance 
and taste, but 
included 
safflower oil 
instead of the 
PUFAs. 
12 weeks ABC 
(hyperactivity 
was primary 
outcome 
measure) 
Peabody Picture 
Vocabulary Test 
Expressive 
Vocabulary Test 
Social 
Responsiveness 
Scale 
Behavioral 
Assessment 
System for 
Children 
Clinical Global 
Impression-
Improvement 
(CGI-I) scale. 
Overall there were 
no statistically 
significant changes 
in any of the 
outcome measures. 
Hyperactivity as 
measured on the 
ABC improved 2.7 
(+/-4.8) points in the 
PUFA group 
compared to 0.3 (+/-
7.2) points in the 
placebo group (p = 
0.40; effect size = 
0.38) but was not 
statistically 
significant. 
 
Autism 
Speaks, the 
Higgins 
Family 
Found-
ation, The 
Emch 
Found-
ation, The 
Taube 
Foundation
,NIH/NCR
R UCSF-
CTSI Grant 
Number 
UL1 
RR024131 
(Dr. Bent) 
and the 
MIND 
Institute. 
Jadad score 
= 5 
Small 
sample size 
(pilot study) 
Correl-ations 
were found 
between 
decreases in 
five fatty 
acid levels 
and 
decreases in 
hyperactivit
y. 
Treatment 
was well 
tolerated. 
Trials of melatonin 
Garstang & 
Wallis 
(2006) 
7 children 
completed the 
study. 
Children with a 
diagnosis of ASD 
(by a 
Melatonin 5mg, 
given at bedtime for 
4 weeks 
Placebo No follow-
up 
Parents kept 
daily sleep logs 
from which the 
Mean and 95% 
confidence interval 
(CI) reported. There 
Coventry 
primary 
care trust 
Jadad score 
= 4  
Possible 
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11 children 
were initially 
enrolled (2 
discontinued 
the study after 
the trial was 
suspended as 
placebo 
capsules were 
empty, 1 
dropped out 
because of a 
house move 
and 1 dropped 
out because 
she was 
involved in a 
child 
protection 
enquiry. 
paediatrician or 
psychiatrist) aged 
4-16, with 
significant 
difficulties 
sleeping at night 
primary outcome 
measures were 
sleep latency, 
total hours of 
sleep, and 
number of night 
awakenings. 
was a decrease in 
mean sleep latency, 
wakings per night 
and increased total 
sleep time with 
melatonin compared 
to baseline & 
placebo 
Sleep latency : 
Baseline 2.60 h [95% 
CI 2.28-2.93]; 
Placebo 1.91 h [1.78-
2.03]; melatonin 
1.06h [0.98-1.13] 
Wakings per night: 
Baseline 0.35 [0.18-
0.53]; Placebo 0.26 
[0.20-0.34]; 
melatonin 0.08 [0.04-
0.12] 
Total sleep : Baseline 
8.05 h [7.65 - 8.44]; 
Placebo 8.75 h [8.56-
8.98]; melatonin 9.84 
h [9.68-9.99] 
The 
melatonin 
and 
placebo 
were 
supplied 
free of 
charge by 
Penn 
Pharmaceu
ticals Ltd. 
 
unblinding 
due to 
problems 
with placebo 
capsules. 
Statistical 
methods 
were not 
clearly 
described 
Adverse 
effects not 
described 
Small 
sample size 
Wright et 
al. (2011) 
20 subjects 
were enrolled, 
17 included in 
analysis. 
Children 
diagnosed with 
ASD based on 
ICD-10 and 
confirmed by 
Autism 
Diagnostic 
Interview—
Revised (ADI) or 
ADOS if 
necessary. 
Included 14 with 
autism, 4 atypical 
autism and 2 with 
AS. Children had 
all been referred 
for serious sleep 
problems. 
Children were 
aged 4-16 years 
and not taking 
psychotropic 
medication. 
2 mg and titrated up 
to 10mg standard 
release melatonin, 1 
hour prior to 
bedtime for 3 months 
Placebo  Parents 
completed sleep 
diaries daily 
which were 
collected 
monthly for 9 
months. Primary 
outcome 
measures were 
sleep latency, 
total sleep time, 
and number of 
wakenings 
Sleep Difficulties 
Questionnaire, 
Developmental 
Behaviour 
Checklist (DBC) 
and General 
Health 
Questionnaire 
collected at the 
start and end of 
each 3-month 
period of 
medication/ 
placebo and on 
completion. A 
Side Effects 
Questionnaire 
was completed at 
start, end and at 
end of each 3-
month period of 
medication/ 
placebo 
Melatonin 
significantly 
improved sleep 
latency (by an 
average of 47 
minutes, p=0.004) 
and total sleep (by 
an average of 52 
minutes, p = 0.002) 
compared to 
placebo, but not 
number of night 
awakenings p = 
0.209. There was a 
statistically 
significant difference 
in the total score of 
the DBC of 6.0 
between melatonin 
and placebo 
(p=0.05). There was 
a significant 
difference in favour 
of melatonin for the 
dysomnias subscale 
of the Sleep 
Difficulties 
questionnaire 
p=0.041) but not 
other subscales. 
Adverse effect 
profile low and 
similar between 
arms. 
York 
Innov-
ations Fund 
and the 
London 
law Trust 
Jadad score 
= 5 
Placebo was 
manufacture
d to be 
identical in 
appearance 
and 
constitution 
as the active 
form. 
Table 2. Published randomised, double-blind, controlled trials of CAM products for the 
treatment of autism. 
4.2 Safety 
Most interventions were associated with only mild adverse effects, although there is a lack 
of long-term safety data available (Table 3).  
4.2.1 High dose pyridoxine and magnesium (HDPM) 
Each of the 15 original studies that investigated the effects of pyridoxine plus or minus 
magnesium was analysed in order to determine adverse effects seen with administration of 
vitamin B6 and/or magnesium to an autistic population. In two studies (Martineau et al. 
1988; Kuriyama et al. 2002), no subjects reported adverse effects. Loose stools and symptoms 
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Complementary medicine Most prevalent adverse effects 
Vitamin B6 + magnesium 
Loose stools, URTI symptoms, nausea, 
excitability 
Vitamin B12 
Hyperactivity and increased mouthing of 
objects 
Dimethylglycine (DMG) Agitation, hyperactivity 
Vitamin C None mentioned 
Iron GI irritation, stained teeth 
Probiotics Rash, diarrhoea, weight loss 
Digestive enzymes 
Hyperactivity, aggression, diarrhoea, 
increased self-stimulatory behaviours, loose 
stools, provocation or red ears and cheeks, 
increased hunger and cessation of eating. 
Secretin 
Rash, hyperactivity, fever, tachycardia, 
vomiting, photosensitivity, increased 
irritability and generalised flushing. 
Polyunsaturated fatty acids 
GI irritation, hyperactivity, behavioural 
worsening, increase the risk of bleeding 
Melatonin 
Tiredness, headache, dizziness, diarrhoea, 
agitation 
Thiamine tetrahydrofuryl disulphide (TTFD) Unpleasant odour 
DMSA Sleep problems, increased tantrums 
Table 3. Major adverse effects observed during trials of selected CAM products in people 
with autism 
of an upper respiratory tract infection (URTI) were each experienced by five subjects in the 
study by Findling et al. (1997), with emesis and fatigue experienced by a single subject. The 
authors hypothesised that the loose stools could have been caused by the cathartic effect of 
magnesium oxide. Lelord et al. (1981) reported nausea in 3 subjects, increased excitability in 3 
subjects and an increase in autistic symptoms in 4 subjects. No other studies mentioned 
monitoring for adverse effects, which does not necessarily indicate that they did not occur. 
Safety reviews of pyridoxine based on data from human and animal studies in wider 
populations were conducted in the 1980s and 1990s (Cohen&Bendich 1986; Bendich&Cohen 
1990). It was found that pyridoxine doses of less than 500mg/day appeared to be safe in 
adults, based on durations of administration ranging from 6 months to 6 years, but that 
daily doses of greater than 500mg for extended periods can cause sensory neuropathy. Since 
April 2006, the Therapeutic Goods Administration in Australia (Therapeutic Goods 
Administration 2006) has required products containing pyridoxine, pyridoxal or 
pyridoxamine to carry a label stating ‘this medicine may be dangerous when used in large 
amounts or for a large period of time’, indicating that these findings are still relevant.   
4.2.2 Vitamin B12 
In the B12 randomised controlled trial by Bertoglio et al. (2010) reported side effects were 
increased hyperactivity and increased mouthing of objects. No serious adverse events were 
reported. The authors concluded that the mild nature, and limited number of side-effects 
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observed, supports that subcutaneous administration of methyl B12 appears safe to use in 
autism. 
4.2.3 Dimethylglycine (DMG) 
In the DMG study by Kern et al. (2001), a greater number of adverse effects occurred in the 
placebo group than in the group receiving DMG. In the DMG group, 1 subject experienced 
difficulty sleeping, another experienced increased aggressiveness and 2 were reported to 
have hyperactivity. These same effects were observed in the placebo group, but in greater 
numbers. Bolman and Richmond (1999) reported that 1 subject became more ‘edgy’ during 
their DMG trial. The average scores on Rimland’s checklist were lower with DMG than 
placebo for the areas of speech, cooperation, understanding, attention, bizarre behaviour, 
tantrums, and activity level, indicating an overall worsening of behaviour with DMG.  
4.2.4 Vitamin C 
The single publication located examining the use of high dose vitamin C in children with 
autism did not mention adverse effects (Dolske et al. 1993). The Natural Medicines 
Comprehensive Database (Natural Medicines Comprehensive Database 2011) and the Mayo 
Clinic (Mayo Clinic 2011) state that Vitamin C supplements are generally regarded as safe if 
used within recommended doses in the general population. Adverse effects are rarely 
reported and are dose-related. Such adverse effects can include nausea, vomiting, heartburn, 
abdominal cramps and headaches. Doses of vitamin C greater than the tolerable upper limit 
of intake have been associated with significant adverse effects such as kidney stones, severe 
diarrhoea, nausea and gastritis. In addition, large doses may precipitate haemolysis in 
patients with glucose-6-phosphate dehydrogenase deficiency (Mayo Clinic 2011). Rare 
reports of flushing, dizziness, faintness and fatigue have also been noted. There are also rare 
reports of scurvy due to tolerance or resistance following cessation after long-term use of 
vitamin C (Mayo Clinic 2011; Natural Medicines Comprehensive Database 2011).  
4.2.5 Iron 
In the iron study conducted by Dosman et al (2007), nine of the 33 (27%) children who 
completed the study experienced GI effects including constipation, loose stools abdominal 
pain and decreased appetite. However, there was a high rate of baseline GI symptoms in 
76% (25/33) of participants. While it was reported that there was exacerbation of GI 
symptoms in some of the children (possibly related to the high dose of elemental iron 
administered) it was stated this was not a common reason for withdrawal from the study. 
Stained teeth were reported for two children (6%). 
4.2.6 Probiotics 
In the probiotic study conducted by Parracho et al. (2010), three subjects withdrew from the 
study because of adverse events. One experienced a skin rash three days after starting the first 
feeding period (probiotic) and withdrew from the study. Two further subjects withdrew from 
the study after the first washout period, one experienced diarrhoea during the probiotic 
feeding period and the other lost 1.2 kg during the probiotic feeding period. 
The Mayo Clinic (Mayo Clinic 2011) and The Natural Medicines Comprehensive Database 
(Natural Medicines Comprehensive Database 2011) agree that the common probiotics 
Lactobacillus acidophilus, Bifidobacteria and Saccharomyces boulardii (taken orally) are well 
www.intechopen.com
 
Complementary Medicine Products Used in Autism - Evidence for Efficacy and Safety 
 
93 
tolerated in the general population and few side effects are reported when used at 
recommended doses. Orally, probiotics can cause GI upset including: abdominal discomfort 
and flatulence. It is reported that this effect is usually transient and mild and subsides with 
continued use (Mayo Clinic 2011; Natural Medicines Comprehensive Database 2011). In 
addition, Bifidobacteria can cause diarrhoea in children (Natural Medicines Comprehensive 
Database 2011).  
Since probiotic preparations contain live and active microorganisms there is concern that 
they might cause pathological infection in some patients. There have been rare reports of 
septicaemia (Lactobacillus acidophilus and Bifidobacteria) and fungaemia (Saccharomyces 
boulardii) in severely ill and/or immunocompromised patients. This effect would not be 
expected to occur from taking oral probiotics in most healthy patients (Mayo Clinic 2011; 
Natural Medicines Comprehensive Database 2011). 
4.2.7 Digestive enzymes 
An open and uncontrolled trial that investigated the efficacy of a dietary enzyme 
supplement (ENZYMAID) in autism also investigated adverse effects (Brudnak et al. 2002). 
Six of the children (13%) enrolled in the study experienced adverse effects including: 
hyperactivity, increased aggression, increased self-stimulatory behaviours, diarrhoea, loose 
stools, provocation or red ears and cheeks, increased hunger and cessation of eating. In 
addition behavioural or medical side affects were listed as reasons for leaving the study. 
In the randomised controlled trial investigating the efficacy of PeptizydeTM, no serious 
adverse effects were noted during the study period (Munasinghe et al. 2010). Two children 
were observed by their parents to have transient behavioural deterioration which they 
initially attributed to commencement on capsules. The behaviours described included 
increased irritability and aggression and inattentiveness. Both families opted to discontinue 
the study, however, follow-up in subsequent weeks showed that the behavioural difficulties 
persisted despite cessation. A further two children were observed by their parents to have 
negative changes in behaviour again initially attributed to capsule use. The behaviours 
included irritability, and difficulties engaging in the classroom. Both opted to withdraw 
from the study, however, on follow-up felt that changing family and school environmental 
factors were probably the significant precipitants. 
4.2.8 Secretin 
No serious adverse events, such as anaphylaxis, were reported in the 14 trials included in 
the systematic review of intravenous secretin use in autism (Williams et al. 2009). Some 
adverse effects possibly attributable to secretin were reported in some studies including 
rash, hyperactivity, fever, tachycardia, vomiting, photosensitivity, increased irritability and 
generalised flushing. 
4.2.9 Polyunsaturated fatty acids (PUFAs) 
GI side effects are reported in the general population following treatment with PUFAs and 
include: nausea, diarrhoea, increased belching, acid/reflux/heartburn/ indigestion, 
abdominal bloating, and abdominal pain. Fishy after-taste is commonly experienced and 
rare reports of skin rash have occurred (Mayo Clinic 2011).  
In the PUFA randomised controlled trial conducted by Amminger et al. (2007) where children 
with autism received a 6 week course of PUFAs or placebo, 1/13 children withdrew due to GI 
complaints and lack of perceived benefit. In another randomised controlled trial conducted by 
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Bent et al. (2010), no serious adverse events were reported during the study in the 27 
participants, and there was no difference in the number of reported non-serious adverse 
events in the two treatment groups. 5/14 patients reported adverse events in the PUFA group 
(2 rashes, 1 upper respiratory infection, 1 nose bleed, 1 increased GI symptoms); 4/13 patients 
reported adverse events in the placebo group (3 increased hyperactivity, 1 increased self-
stimulatory behaviour). In an uncontrolled study by Patrick and Salik (Patrick&Salik 2006), 
2/22 children withdrew due to reports of increased physical activity, but no other adverse 
effects were noted. In another uncontrolled study, a ‘‘few parents’’ reported ‘‘increased 
hyperactivity and behavioral problems’’ (Bell et al. 2004). Two uncontrolled studies (Meguid et 
al. 2008; Politi et al. 2008) and a case report (Johnson&Hollander 2003) did not discuss whether 
adverse events were assessed. Meiri et al. (2009) conducted an open study where 9 children 
with autism received a 12 week course of PUFAs and no adverse effects were reported. A 
systematic review by Bent et al. (2009) that examined safety and efficacy of PUFAs in autism 
highlighted that most studies indicate that omega-3 fatty acids are relatively safe, although 
there are some concerns that it may increase the risk of bleeding (and therefore should be 
avoided in persons at increased risk for bleeding). 
4.2.10 Melatonin 
In the randomised controlled trial of melatonin conducted by Garstang and Wallis (2006), 
adverse effects were not described. In the randomised controlled trial in 17 children with 
autism by Wright et al. (2011) adverse effects were low and similar between the two arms. The 
side effects that occurred more frequently in the melatonin arm were as follows: daytime 
drowsiness, reduced appetite, reduced alertness and diarrhoea however, differences in the 
frequency of these adverse effects were not statistically significant. The observational 
retrospective study in 107 children with autism conducted by Andersen et al. (2008) reported 3 
children experienced mild adverse effects including increased enuresis, morning sleepiness 
and "fogginess". In Paavonen et al.'s study (2003) in a cohort of 15 children with AS one subject 
reported extreme tiredness, diarrhoea, headache and dizziness; one reported mild tiredness 
and headache on days 1 and 2 of the study and another reported prolonged wakeful periods at 
the beginning of the treatment. In the open prospective study in 20 young children with 
autism conducted by Gianotti et al. (2006) and the observational retrospective study in six 
adults with autism by Galli-Carminati (2009) no adverse effects were reported but were 
monitored for. A recent case series reported melatonin induced agitation in three patients with 
intellectual disability (Richings&Feroz-Nainar 2010). 
In a recent review of the safety and efficacy of exogenous melatonin used for secondary 
sleep disorder in a more generalised population (Buscemi et al. 2006), it was reported that 
the most frequently-occurring adverse effects were headache, dizziness, nausea and 
drowsiness. However, the incidence of these effects was found to be similar during both the 
placebo and melatonin phases of trials. The safety review encompassed a total of 17 studies, 
both controlled and uncontrolled, with 651 participants overall. No mention of an increase 
in seizure frequency being caused by melatonin administration was made. 
4.2.11 Chelating therapies 
Lonsdale et al. (2002) examined the efficacy of the chelating agent TTFD in autism in an open 
pilot study in children with autism aged 3 to 8 (n=10) The only adverse effect documented by 
Lonsdale et al. (2002) was parental reports of a ‘skunk-like odour’ in 9/10 subjects. There was 
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also a worsening of autistic symptoms in 1 subject. According to the Mayo Clinic, long-term 
doses of thiamine up to 200mg daily are considered non-toxic, although doses greater than 
100mg may result in drowsiness or muscle relaxation (Mayo Clinic 2011). 
Adverse effects were monitored for in the study by Adams et al (2009a; 2009b) examining 
the chelating agent DMSA in autism. In phase one of the study: one “mild adverse reaction” 
(lethargy and decreased appetite) was reported. In Phase two, four participants dropped out 
due to adverse effects including sleep problems (one on DMSA); behaviour and some skills 
worsened (one on DMSA); worsened behaviour (two on placebo). Additionally, two 
participants on DMSA who ended the study early had moderate sleep problems (both 
children) and increased tantrums (one child) that resolved on stopping treatment. 
Despite the availability of the studies of the chelating agent DMSA in autism that showed 
some benefits, and acceptable levels of tolerability in a limited number of children, there are 
significant concerns about the safety of chelation therapy in the management of autism. It is 
notable that a randomised controlled trial designed to examine the safety and efficacy of 
DMSA for mercury chelation in autism was halted by the US National Institute for Mental 
Health after an assessment that the study treatment presented more than minimal risk 
(Mitka 2008). This was partly due to a study in rats designed to assess the effects of chelation 
with DMSA following lead exposure. This study had the unexpected finding that a single 3-
week course of succimer treatment in rats not exposed to lead during their early 
development produced lasting cognitive dysfunction when assessed over a 7-month period 
(Stangle et al. 2007). 
Furthermore the US Food and Drug Administration (FDA) issued a warning in 2010 to 
manufacturers of a number of different chelation products available without prescription 
and readily obtained over the internet (FDA, 2011). The FDA has indicated that the 
companies have not provided evidence to substantiate their claims that their products are 
safe and effective in treating conditions such as ASD. The FDA has threatened legal action if 
companies continue to make unsubstantiated claims. 
4.2.12 Others 
No studies of any description involving children with autism were located for the 
remainder of the interventions under investigation. Hence, safety of the remaining CAM 
products in autism could not be elucidated. The authors refer the reader to the monographs 
available through the Mayo Clinic website (Mayo Clinic 2011) and the Natural Medicines 
Comprehensive Database (Natural Medicines Comprehensive Database 2011) that both 
report side effects associated with taking a range of supplements in the general population. 
5. Conclusion 
Available evidence for efficacy and safety for a range of CAM products has been compiled 
that will equip health professionals with information so they can sensitively disclose and 
discuss CAM product usage with patients and their families. Therefore, health professionals 
can ethically and responsibly assist patients and caregivers with their decision making 
regarding CAM product usage. Pleasingly, when medical practitioners were surveyed 
regarding which CAMs they recommended to caregivers for their children with autism it 
was revealed it was the agents for which there is emerging evidence for benefit and 
reasonable safety profiles i.e. multivitamins (49%), PUFAs (25%), melatonin (25%) and 
probiotics (19%) (Golnik&Ireland 2009). On the other hand, 61% of medical practitioners 
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surveyed reported they discourage use of chelation therapy which does not have evidence 
of benefit in the management of autism and potential safety risks (Golnik&Ireland 2009). 
The information compiled can also be accessed by researchers. This study highlights there is 
an urgent need for more well-designed clinical trials to improve the evidence base on which 
people with autism, caregivers and health care professionals can make decisions about 
treatment options. Health care professionals and caregivers need to be informed that for 
many CAM products, the rationale for use is only theoretical and not biologically proven. 
Further, the use of CAM products in autism is not risk-free and often lacks sound clinical 
evidence for efficacy. 
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